UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 52

Sortiert nach

Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia

Nature medicine, 2020-03, Vol.26 (3), p.379-386

2020

Volltextzugriff (PDF)

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease

Nature communications, 2020-04, Vol.11 (1), p.1683-1683, Article 1683

2020

Volltextzugriff (PDF)

Constitutive secretion of tau protein by an unconventional mechanism

Neurobiology of disease, 2012-12, Vol.48 (3), p.356-366

2012

Volltextzugriff (PDF)

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

JAMA : the journal of the American Medical Association, 2020-08, Vol.324 (8), p.772

2020

Volltextzugriff (PDF)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

EMBO molecular medicine, 2019-12, Vol.11 (12), p.e11170-n/a

2019

Volltextzugriff (PDF)

P4‐540: CSF PTAU‐217 PERFORMS BETTER THAN PTAU‐181 IN DETECTING ABNORMAL RETENTION OF 18 F‐FLORTAUCIPIR AND DISCRIMINATING ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS

Alzheimer's & dementia, 2019-07, Vol.15 (7S_Part_29)

2019

Volltextzugriff (PDF)

Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography

Alzheimer's & dementia, 2018-08, Vol.14 (8), p.989-997

2018

Volltextzugriff (PDF)

Author Response to Comment on “Plasma calcitonin gene‐related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion”

Headache, 2024-01, Vol.64 (1), p.121-121

2024

Volltextzugriff (PDF)

Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression

The Journal of biological chemistry, 2011-09, Vol.286 (39), p.34457-34467

2011

Volltextzugriff (PDF)

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease

Science advances, 2020-04, Vol.6 (16), p.eaaz2387-eaaz2387

2020

Volltextzugriff (PDF)

EXPLORING AV1451 BINDING THROUGH BIOCHEMICAL AND BIOPHYSICAL ANALYSIS OF PHF TAU FROM HUMAN AND TG4510 BRAINS WITH ELECTRON MICROSCOPY

Alzheimer's & dementia, 2016-07, Vol.12 (7), p.P844-P845

2016

Volltextzugriff (PDF)

P4‐540: CSF PTAU‐217 PERFORMS BETTER THAN PTAU‐181 IN DETECTING ABNORMAL RETENTION OF 18F‐FLORTAUCIPIR AND DISCRIMINATING ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS

Alzheimer's & dementia, 2019-07, Vol.15, p.P1523-P1523

2019

Volltextzugriff (PDF)

CSF PTAU-217 PERFORMS BETTER THAN PTAU-181 IN DETECTING ABNORMAL RETENTION OF 18F-FLORTAUCIPIR AND DISCRIMINATING ALZHEIMER’S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS

Alzheimer's & dementia, 2019-07, Vol.15 (7), p.P1523-P1523

2019

Volltextzugriff (PDF)

Plasma calcitonin gene–related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion

Headache, 2023-10, Vol.63 (9), p.1240-1250

2023

Volltextzugriff (PDF)

Biochemical and kinetic characterization of BACE1: investigation into the putative species‐specificity for β‐ and β′‐cleavage sites by human and murine BACE1

Journal of neurochemistry, 2004-12, Vol.91 (6), p.1249-1259

2004

Volltextzugriff (PDF)

Evaluation of Plasma Calcitonin Gene-Related Peptide as a Biomarker for Painful Temporomandibular Disorder and Migraine

Journal of pain research, 2023-01, Vol.16, p.2331-2346

2023

Volltextzugriff (PDF)

Phospho‐tau217 and phospho‐tau181 in plasma and CSF as biomarkers for Alzheimer’s disease

Alzheimer's & dementia, 2020-12, Vol.16, p.n/a

2020

Volltextzugriff (PDF)

Phospho‐tau217 and phospho‐tau181 in plasma and CSF as biomarkers for Alzheimer’s disease: Clinical study results of AD blood biomarkers

Alzheimer's & dementia, 2020-12, Vol.16 (S5)

2020

Volltextzugriff (PDF)

P3‐071: Exploring AV1451 Binding Through Biochemical and Biophysical Analysis of PHF TAU From Human and TG4510 Brains with Electron Microscopy

Alzheimer's & dementia, 2016-07, Vol.12 (7S_Part_17), p.P844-P845

2016

Volltextzugriff (PDF)

A vast difference in the levels of insoluble tau in commonly used tau mouse models

Alzheimer's & dementia, 2013-07, Vol.9 (4), p.P819-P819

2013

Volltextzugriff (PDF)

P4–314: A vast difference in the levels of insoluble tau in commonly used tau mouse models

Alzheimer's & dementia, 2013-07, Vol.9 (4S_Part_21), p.P819-P819

2013

Volltextzugriff (PDF)

O2‐05‐04: PLASMA PTAU181 LEVELS REFLECT [18F]AV1451 TAU PET UPTAKE ACROSS THE TAUOPATHY SPECTRUM

Alzheimer's & dementia, 2019-07, Vol.15 (7S_Part_10), p.P547-P547

2019

Volltextzugriff (PDF)

PLASMA PTAU181 LEVELS REFLECT [18F]AV1451 TAU PET UPTAKE ACROSS THE TAUOPATHY SPECTRUM

Alzheimer's & dementia, 2019-07, Vol.15 (7), p.P547-P547

2019

Volltextzugriff (PDF)

Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau-PET and amyloid-PET

Alzheimer's & dementia, 2018-04, Vol.14 (8), p.989-997

2018

Volltextzugriff (PDF)

1 – 25 von 52

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(48)

Publikationsform

Artikel
(52)

Sprache

Englisch
(52)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease

Constitutive secretion of tau protein by an unconventional mechanism

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

P4‐540: CSF PTAU‐217 PERFORMS BETTER THAN PTAU‐181 IN DETECTING ABNORMAL RETENTION OF 18 F‐FLORTAUCIPIR AND DISCRIMINATING ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS

Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration

Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography

Author Response to Comment on “Plasma calcitonin gene‐related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion”

Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease

EXPLORING AV1451 BINDING THROUGH BIOCHEMICAL AND BIOPHYSICAL ANALYSIS OF PHF TAU FROM HUMAN AND TG4510 BRAINS WITH ELECTRON MICROSCOPY

P4‐540: CSF PTAU‐217 PERFORMS BETTER THAN PTAU‐181 IN DETECTING ABNORMAL RETENTION OF 18F‐FLORTAUCIPIR AND DISCRIMINATING ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS

CSF PTAU-217 PERFORMS BETTER THAN PTAU-181 IN DETECTING ABNORMAL RETENTION OF 18F-FLORTAUCIPIR AND DISCRIMINATING ALZHEIMER’S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS

Plasma calcitonin gene–related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion

Biochemical and kinetic characterization of BACE1: investigation into the putative species‐specificity for β‐ and β′‐cleavage sites by human and murine BACE1

Evaluation of Plasma Calcitonin Gene-Related Peptide as a Biomarker for Painful Temporomandibular Disorder and Migraine

Phospho‐tau217 and phospho‐tau181 in plasma and CSF as biomarkers for Alzheimer’s disease

Phospho‐tau217 and phospho‐tau181 in plasma and CSF as biomarkers for Alzheimer’s disease: Clinical study results of AD blood biomarkers

P3‐071: Exploring AV1451 Binding Through Biochemical and Biophysical Analysis of PHF TAU From Human and TG4510 Brains with Electron Microscopy

A vast difference in the levels of insoluble tau in commonly used tau mouse models

P4–314: A vast difference in the levels of insoluble tau in commonly used tau mouse models

O2‐05‐04: PLASMA PTAU181 LEVELS REFLECT [18F]AV1451 TAU PET UPTAKE ACROSS THE TAUOPATHY SPECTRUM

PLASMA PTAU181 LEVELS REFLECT [18F]AV1451 TAU PET UPTAKE ACROSS THE TAUOPATHY SPECTRUM

Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau-PET and amyloid-PET

Suchergebnisse filtern